Aurobindo Pharma
- Market Cap
- ₹1,03,510 Cr
- P/E
- 26.05
Key Fundamentals
MidcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 12.90%
- Debt to Equity
- 0.22
- EPS (TTM)
- ₹69.05
- Book Value
- ₹684.77
- Market Cap
- ₹1,03,510 Cr
- P/E (TTM)
- 26.05
- P/B
- 2.63
- ROE
- 10.10%
- Dividend Yield
- 0.39%
- EBITDA
- ₹7,338 Cr
- 52W High
- ₹1,859.90
- 52W Low
- ₹1,106.00
- Day Range
- ₹1,788.10 – ₹1,817.50
- Volume
- 8,11,247
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| 1,799.00 | 26.05 | 1,03,510 | 2.63 | 0.39% | 10.10% | 12.90% | 36,913 | 3,987 | |
| Median 8 companies | 1,841.95 | 41.35 | 1,21,840 | 4.69 | 0.48% | 16.25% | 16.65% | 29,259 | 3,109 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 46
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 82
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 37
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 50
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 52
- Average
- Trend strength, vol-adjusted 12% weight
- Ownership
- 52
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
4- Stock is trading at 2.63 times its book value
- The company has delivered a poor sales growth of 6.32% over past five years.
- Company has a low return on equity of 10.8% over last 3 years.
- Company might be capitalizing the interest cost
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 1 | 6 | 12 |
| Oscillators | Bullish | 0 | 6 | 3 |
| Moving Averages | Strong Bullish | 1 | 0 | 9 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 60.45
- Neutral
- MACD (12,26,9)
- 37.43
- Bullish
- SMA (50)
- 1,704.58
- Bullish
- SMA (200)
- 1,504.03
- Bullish
As of
Analyst Rating
18 of 27 analysts rate Buy, 5 Hold, 4 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +9.35% |
|---|---|
| 5Y | +6.32% |
| 3Y | +10.63% |
| 1Y | +6.08% |
| TTM | +13.52% |
Net profit
| 10Y | +5.64% |
|---|---|
| 5Y | −8.07% |
| 3Y | +22.02% |
| 1Y | +0.55% |
| TTM | +16.54% |
Operating cash flow
| 10Y | +14.55% |
|---|---|
| 5Y | +10.67% |
| 3Y | +32.29% |
| 1Y | +40.79% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −2.77 pp |
|---|---|
| 5Y | −0.89 pp |
| 3Y | +5.50 pp |
| 1Y | −0.27 pp |
| TTM | +0.11 pp |
Revenue by year
| Mar 2017 | ₹14,910 Cr |
|---|---|
| Mar 2018 | ₹16,463 Cr |
| Mar 2019 | ₹19,564 Cr |
| Mar 2020 | ₹23,099 Cr |
| Mar 2021 | ₹24,775 Cr |
| Mar 2022 | ₹23,455 Cr |
| Mar 2023 | ₹24,855 Cr |
| Mar 2024 | ₹29,002 Cr |
| Mar 2025 | ₹31,724 Cr |
| Mar 2026 | ₹33,653 Cr |
Net profit by year
| Mar 2017 | ₹2,301 Cr |
|---|---|
| Mar 2018 | ₹2,423 Cr |
| Mar 2019 | ₹2,364 Cr |
| Mar 2020 | ₹2,844 Cr |
| Mar 2021 | ₹5,334 Cr |
| Mar 2022 | ₹2,647 Cr |
| Mar 2023 | ₹1,928 Cr |
| Mar 2024 | ₹3,169 Cr |
| Mar 2025 | ₹3,484 Cr |
| Mar 2026 | ₹3,503 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Aurobindo Pharma trades at a market cap of ₹1,03,229 Cr with a PE of 25.98x as of 2026-11-17. The stock has delivered a 45% return over the past one year and is near its 52-week high of ₹1,859.9, while carrying a modest debt-to-equity ratio of 0.21 and showing improved recent profit growth of 19% TTM against a weaker five-year compounded profit growth of just 1%.
- Strong recent stock performance with a 1-year CAGR of 45%, significantly outperforming its 10-year CAGR of 10%
- TTM sales growth of 14% marks a notable acceleration versus the 5-year compounded sales growth of 6%
- TTM profit growth of 19% represents a sharp recovery from a muted 1% compounded profit growth over 5 years
- Conservative balance sheet with a debt-to-equity ratio of just 0.21, providing financial flexibility for future expansion
- 3-year compounded profit growth of 23% indicates a sustained earnings recovery trend, not a one-off spike
- 3-year stock CAGR of 21% and 5-year stock CAGR of 23% suggest consistent wealth creation over medium-term horizons
- 10-year compounded sales growth of 9% demonstrates long-term revenue scaling ability in a competitive generic pharma landscape
- Current price of ₹1,794.1 is 62% above its 52-week low of ₹1,106, reflecting strong upward momentum over the trailing year
- 5-year compounded sales growth of only 6% indicates a prolonged period of sluggish top-line expansion
- 3-year average return on equity of roughly 11% and last year ROE of 10% remain below the 10-year average of 14%, suggesting declining capital efficiency
- Stock trades at 2.62x book value as of 2026-11-17, which is elevated for a company with a current ROE of only 9.25%
- 5-year compounded profit growth of just 1% highlights that the recent earnings recovery follows years of near-stagnant profitability
- ROCE of 13.58% and ROE of 9.25% show a meaningful gap, and the company may be capitalizing interest costs which could flatter reported earnings
- Dividend yield of only 0.39% offers minimal income return to shareholders relative to the PE of 25.98x
- PE of 25.98x against an EPS of ₹69.05 implies the market is pricing in sustained high growth, which the 5-year profit CAGR of 1% has not historically supported
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Aurobindo Pharma delivered a strong Q2FY27 with record revenue of ₹10,263 crore and 32.5% profit growth, beating estimates across all parameters. The key risk is the USFDA OAI classification on a subsidiary facility, though the company says it has no financial or operational impact. The stock is up ~51% in 2026, reflecting strong execution in the US and Europe. With full Lannett integration and biosimilar ramp-up, FY28 outlook appears constructive if regulatory issues remain contained.
- USFDA OAI for subsidiary plant Nov 11
USFDA issued an OAI classification with 4 observations for a subsidiary's manufacturing facility inspected Aug 17-21, 2026. Shares fell 3% over two sessions, snapping a 12-day winning streak.
- Q2FY27 profit beats estimates Nov 4
Consolidated net profit rose 32.5% YoY to ₹1,124-1,126 crore on highest-ever quarterly revenue of ₹10,263 crore (+23.9% YoY). EBITDA jumped 28.5% to ₹2,156 crore with margin expanding 77 bps to 21%.
- Strong US and Europe growth Nov 4
US revenue grew 25.2% YoY to ₹4,555 crore and Europe surged 27.5% to ₹3,161 crore. The company received 12 USFDA approvals and launched 10 US products including generic Advair.
- Robust cash and dividend declared Nov 4
Free cash flow of $146 million in Q2; net cash position of $189 million as of Sep 30, 2026. Board approved interim dividend of ₹7 per share with Nov 11 record date.
- Apitoria Unit-6 gets VAI status Nov 21
Apitoria Pharma Unit-6 received a VAI classification from USFDA after 3 inspection observations. No regulatory action recommended and inspection is officially closed with EIR received.
- Shareholder vote on director, pay Nov 18
Postal ballot initiated for M.R. Kumar's second term as Independent Director and remuneration revisions for top executives effective Nov 1, 2026.
- API subsidiaries merger approved Nov 4
Board approved merger of wholly owned subsidiaries Auroactive and Apitoria to consolidate API operations and improve efficiency.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 | 10,263 |
| Expenses | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 | 7,271 | 8,110 |
| Operating Profit | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 | 1,880 | 2,153 |
| OPM % | 19% | 22% | 22% | 21% | 20% | 20% | 21% | 20% | 20% | 21% | 20% | 21% | 21% |
| Other Income | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 121 | 123 | 117 | 264 | 168 |
| Interest | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 | 102 |
| Depreciation | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 | 531 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | — | — | −40.18 | — |
| PBT | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,517 | 1,688 |
| Tax % | 30% | 26% | 26% | 31% | 32% | 30% | 32% | 32% | 34% | 32% | 29% | 32% | 33% |
| Net Profit | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 | 1,124 |
| EPS (₹) | 12.92 | 15.98 | 15.51 | 15.69 | 14.07 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.95 | 19.57 |
| YoY Sales growth | 26 | 15 | 17 | 10 | 8 | 9 | 11 | 4 | 6 | 8 | 6 | 16 | 24 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,103 | 13,772 | 14,910 | 16,463 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 | 36,913 |
| Expenses | 9,524 | 10,579 | 11,469 | 12,691 | 15,612 | 18,249 | 19,497 | 19,060 | 21,148 | 23,176 | 25,164 | 26,783 | 29,357 |
| Operating Profit | 2,579 | 3,193 | 3,441 | 3,772 | 3,952 | 4,849 | 5,278 | 4,396 | 3,707 | 5,826 | 6,560 | 6,870 | 7,556 |
| OPM % | 21% | 23% | 23% | 23% | 20% | 21% | 21% | 19% | 15% | 20% | 21% | 20% | 20% |
| Other Income | 81 | 200 | 115 | 105 | 70 | 166 | 3,195 | 152 | 291 | 366 | 613 | 404 | 632 |
| Interest | 160 | 257 | 67 | 78 | 263 | 305 | 74 | 49 | 140 | 290 | 457 | 384 | 395 |
| Depreciation | 333 | 392 | 428 | 558 | 668 | 967 | 1,055 | 1,127 | 1,245 | 1,522 | 1,649 | 1,778 | 1,961 |
| PBT | 2,168 | 2,744 | 3,061 | 3,241 | 3,091 | 3,743 | 7,344 | 3,373 | 2,612 | 4,380 | 5,066 | 5,110 | 5,832 |
| Tax % | 28% | 26% | 25% | 25% | 24% | 24% | 27% | 22% | 26% | 28% | 31% | 31% | — |
| Net Profit | 1,571 | 2,024 | 2,301 | 2,423 | 2,364 | 2,844 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 | 3,987 |
| EPS (₹) | 26.98 | 34.61 | 39.29 | 41.36 | 40.36 | 48.56 | 91.05 | 45.20 | 32.90 | 54.15 | 60.02 | 60.34 | 69.05 |
| Div. Payout % | 8% | 7% | 6% | 6% | 6% | 6% | 4% | 20% | 23% | 8% | 0% | 7% | — |
| Sales growth | 50 | 14 | 8 | 10 | 19 | 18 | 7 | −5 | 6 | 17 | 9 | 6 | 14 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 | 58 |
| Reserves | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 | 37,833 | 39,342 |
| Borrowings | 4,451 | 5,041 | 3,364 | 4,770 | 6,967 | 5,826 | 5,339 | 2,851 | 5,286 | 6,648 | 8,263 | 8,073 | 8,630 |
| Other Liabilities | 3,303 | 3,568 | 3,464 | 4,492 | 5,414 | 6,113 | 6,147 | 6,211 | 7,379 | 8,227 | 8,566 | 12,232 | 13,725 |
| Total Liabilities | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,196 | 61,754 |
| Fixed Assets | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,396 | 9,374 | 10,532 | 11,024 | 14,493 | 14,794 | 17,407 | 21,415 |
| CWIP | 420 | 848 | 1,458 | 1,583 | 1,668 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 4,900 | 5,214 | 3,487 |
| Investments | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 | 1,051 | 354 |
| Other Assets | 8,765 | 10,745 | 9,662 | 12,527 | 15,768 | 16,827 | 20,390 | 18,362 | 22,549 | 25,983 | 29,536 | 34,525 | 36,498 |
| Total Assets | 12,910 | 15,896 | 16,200 | 20,942 | 26,271 | 28,765 | 33,416 | 33,638 | 39,505 | 44,717 | 49,482 | 58,196 | 61,754 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,016 | 2,387 | 2,435 | 3,925 | 5,526 |
| Investing | −1,017 | −1,446 | −1,787 | −1,927 | −2,904 | −1,563 | 597 | −3,211 | −3,971 | −4,242 | −1,866 | −2,630 |
| Financing | 93 | 365 | −1,915 | 864 | 1,919 | −1,947 | −1,365 | −2,969 | 1,814 | 800 | 120 | −1,269 |
| Net Cash Flow | 313 | 340 | −424 | 892 | 666 | 871 | 2,561 | −1,164 | 230 | −1,007 | 2,178 | 1,628 |
| Free Cash Flow | 491 | −146 | 1,594 | 714 | 114 | 2,969 | 1,503 | 2,693 | −323 | −1,067 | 1,408 | 2,468 |
| CFO/EBITDA | 67 | 67 | 118 | 70 | 61 | 106 | 87 | 143 | 84 | 72 | 86 | 107 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 107 | 122 | 68 | 68 | 64 | 68 | 52 | 62 | 66 | 61 | 66 | 77 |
| Inventory Days | 239 | 240 | 246 | 317 | 304 | 289 | 333 | 272 | 275 | 284 | 295 | 326 |
| Days Payable | 136 | 146 | 122 | 128 | 107 | 97 | 103 | 97 | 125 | 129 | 117 | 151 |
| Cash Conversion Cycle | 210 | 217 | 191 | 257 | 260 | 260 | 282 | 237 | 216 | 216 | 244 | 252 |
| Working Capital Days | 50 | 44 | 51 | 50 | 25 | 35 | 52 | 84 | 55 | 66 | 49 | 44 |
| ROCE % | 27% | 27% | 25% | 23% | 18% | 19% | 18% | 13% | 9% | 14% | 14% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Aurobindo Pharma insights
71 extracted metrics across FY07–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT
- Q1 FY27 concall · Aug 2026Transcript PPT
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026PPT
- Q3 FY26 concall · Feb 2026Transcript PPT
- 10 Jun 2026
- 11 Mar 2025
- 20 Dec 2023
- 20 Oct 2022
- 6 Aug 2021
- General announcements 11 Nov 2026
Frequently Asked Questions about Aurobindo Pharma
What does Aurobindo Pharma Ltd do?
Where is Aurobindo Pharma Ltd (AUROPHARMA) listed?
Which sector does Aurobindo Pharma Ltd belong to?
What is the market capitalisation of Aurobindo Pharma Ltd?
What is the PE ratio of Aurobindo Pharma Ltd?
What is the 52-week high and low of Aurobindo Pharma Ltd?
Does Aurobindo Pharma Ltd pay dividends?
What is the Return on Equity (ROE) of Aurobindo Pharma Ltd?
Company Information
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AUROPHARMA.md for Aurobindo Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.